Natasha S. Namjoshi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Natasha S. Namjoshi has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Elysia Alvarez
Division of Pediatric Hematology/Oncology Department of Pediatrics School of Medicine University of California Davis Davis California USA
1 shared publication Jennifer L. Rosenthal
Division of Pediatric Hospital Medicine, University of California Davis School of Medicine, Sacramento, CA, USA
1 shared publicationJong H. Chung
Division of Pediatric Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA, USA
1 shared publication- Lena E. Winestone
Division of Pediatric Allergy, Immunology, and Bone Marrow Transplantation, University of California San Francisco, San Francisco, CA
1 shared publication Lori Muffly
Department of Medicine Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, USA
1 shared publicationMarcio H. Malogolowkin
Division of Pediatric Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA, USA
1 shared publication
Latest Publications
- 23 August 2022
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 63 (13) , 1-9
Treatment-related toxicities associated with hospitalization in children, adolescents, and young adults with acute lymphoblastic leukemia: population level analysis
Treatment-related toxicities (TRTs) are a potential cause of survival disparities in patients with acute lymphoblastic leukemia (ALL). We aimed to identify the most frequent TRTs associated with hospitalizations at a population level in children, adolescents and young adults (AYAs). We used the California Cancer Registry linked to a statewide hospital discharge database to identify children and AYAs with TRTs within 3 years of diagnosis. We assessed the frequency of TRTs, length of stay (LOS), admission rates associated with TRTs and TRTs impact on survival. Febrile neutropenia, hypertension, and thrombocytopenia were the most common TRTs for both children and AYAs. AYAs had longer median LOS compared to children for most toxicities. AYAs at non-specialized cancer centers (SCCs) had higher frequency of admissions associated with TRTs compared to non-SCC. Cardiovascular, respiratory, gastrointestinal, renal, and infectious TRTs were associated with worse survival. This study demonstrates the burden of TRTs in patients with ALL.
- 23 August 2022
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 63 (13) , 1-9
Treatment-related toxicities associated with hospitalization in children, adolescents, and young adults with acute lymphoblastic leukemia: population level analysis
Treatment-related toxicities (TRTs) are a potential cause of survival disparities in patients with acute lymphoblastic leukemia (ALL). We aimed to identify the most frequent TRTs associated with hospitalizations at a population level in children, adolescents and young adults (AYAs). We used the California Cancer Registry linked to a statewide hospital discharge database to identify children and AYAs with TRTs within 3 years of diagnosis. We assessed the frequency of TRTs, length of stay (LOS), admission rates associated with TRTs and TRTs impact on survival. Febrile neutropenia, hypertension, and thrombocytopenia were the most common TRTs for both children and AYAs. AYAs had longer median LOS compared to children for most toxicities. AYAs at non-specialized cancer centers (SCCs) had higher frequency of admissions associated with TRTs compared to non-SCC. Cardiovascular, respiratory, gastrointestinal, renal, and infectious TRTs were associated with worse survival. This study demonstrates the burden of TRTs in patients with ALL.